Cited by 169Regulation of Appetite and ObesityPancreatic function and diabetesDiabetes Management and Research

Insulin action in the brain contributes to glucose lowering during insulin treatment of diabetes

Open access
Gelling, Richard W., Morton, Gregory J., Morrison, Christopher D., Niswender, Kevin D., Myers, Martin G., Rhodes, Christopher J., Schwartz, Michael W.·2006·Cell Metabolism

Abstract

To investigate the role of brain insulin action in the pathogenesis and treatment of diabetes, we asked whether neuronal insulin signaling is required for glucose-lowering during insulin treatment of diabetes. Hypothalamic signaling via the insulin receptor substrate-phosphatidylinositol 3-kinase (IRS-PI3K) pathway, a key intracellular mediator of insulin action, was reduced in rats with uncontrolled diabetes induced by streptozotocin (STZ-DM). Further, infusion of a PI3K inhibitor into the third cerebral ventricle of STZ-DM rats prior to peripheral insulin injection attenuated insulin-induced glucose lowering by approximately 35%-40% in both acute and chronic insulin treatment paradigms. Conversely, increased PI3K signaling induced by hypothalamic overexpression of either IRS-2 or protein kinase B (PKB, a key downstream mediator of PI3K action) enhanced the glycemic response to insulin by approximately 2-fold in STZ-DM rats. We conclude that hypothalamic insulin signaling via the IRS-PI3K pathway is a key determinant of the response to insulin in the management of uncontrolled diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmet.2005.11.013

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Both peripheral and central insulin signaling are impaired in obese or diabetic states.

    “Both, peripheral and central insulin signaling are impaired in obese or diabetic states.150, 151, 152, 153, 154”

    From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [154]

    The Results (page unavailable) report reduced hypothalamic IRS-PI3K signaling in rats with streptozotocin-induced diabetes and describe insulin resistance after prolonged insulin deficiency. The paper does not show impaired peripheral insulin signaling directly or establish the claim for obesity or diabetic states generally. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Increasing hypothalamic PI3K signaling by local overexpression of IRS-2 increases peripheral insulin sensitivity in STZ-induced uDM rats.

    “increasing hypothalamic PI3K signaling, a major intracellular mediator of insulin action, by local overexpression of IRS-2 increases peripheral insulin sensitivity in rats with uDM induced by STZ (65).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gelling, R. W., Morton, G. J., Morrison, C. D., Niswender, K. D., Myers, M. G., Rhodes, C. J., & Schwartz, M. W.
Affiliations
  • University of Washington (US)
  • University of Michigan (US)
Corresponding author
Schwartz, Michael W.
Venue
Cell Metabolism
Publisher
Elsevier BV
Published
2006-01
Volume
3
Issue
1
Pages
67-73
ISSN
1550-4131 (ISSN-L)
OpenAlex
W2052985185
Cited by
169
References
27
Citations by year
2026: 2 · 2025: 1 · 2023: 3 · 2022: 4 · 2021: 7 · 2020: 4 · 2019: 10 · 2018: 8 · 2017: 9 · 2016: 9 · 2015: 12 · 2014: 8 · 2013: 9 · 2012: 18
FWCI
5.46
Type
journal article
Language
en
Open access
Locations
  • Cell Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Washington
  • National Institutes of Health (2r01dk012829-36, DK‐12829, NS32273)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK 12829, R01DK052989, DK68340, DK-52989)
  • National Institute of Neurological Disorders and Stroke (NS-32273)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
hypothalamus, insulin signaling, insulin receptor substrate, phosphatidylinositol 3-kinase, Akt, insulin receptor substrate 2, streptozotocin-induced diabetes, insulin resistance, glucose homeostasis
MeSH terms
Phosphoinositide-3 Kinase Inhibitors, Animals, Blood Glucose, Brain, Chromones, Diabetes Mellitus, Experimental, Insulin, Male, Morpholines, Nerve Tissue Proteins, Rats, Sprague-Dawley, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review